MedPath

Investigation of the safety and efficacy of semaglutide s.c. in combination with NNC0480-0389 in participants with type 2 diabetes - a dose finding study(NN9389-4606)

Phase 2
Conditions
Type 2 diabetes mellitus
Registration Number
JPRN-jRCT2031210474
Lead Sponsor
Oyatani Akihito
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
495
Inclusion Criteria

Participants treated with diet and exercise as monotherapy or in combination with stable daily dose of any metformin formulations

Exclusion Criteria

Severe heart failure, History of chronic pancreatitis, other

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath